We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current 0M4 market cap is 38.27M. The company's latest EPS is USD -0.5601 and P/E is -0.62.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 828k | 43k | 26.58M | 36.86M | 40.5M |
| Operating Income | -88.11M | -168.86M | -203.77M | -179.64M | -73.34M |
| Net Income | -88.05M | -170.06M | -204.21M | -171.64M | -69.19M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 273.4M | 206.11M | 334.34M | 226.06M | 144.66M |
| Total Liabilities | 45.31M | 84.37M | 242.28M | 189.16M | 154.17M |
| Total Equity | 228.09M | 121.74M | 92.06M | 36.9M | -9.51M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -74.7M | -139.99M | -49.36M | -168.88M | -82.34M |
| Investing | 37.03M | -648k | -152.72M | 119.88M | 11.44M |
| Financing | 230.41M | 63.65M | 153.02M | 94.68M | 4.09M |
| Market Cap | 38.27M |
| Price to Earnings Ratio | -0.62 |
| Price to Sales Ratio | 1.07 |
| Price to Cash Ratio | 0.4 |
| Price to Book Ratio | -4.55 |
| Dividend Yield | - |
| Shares Outstanding | 123.53M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.01 (3.11%) |
| Company Name | Mersana Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.mersana.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
